ACARIX AB

Acarix reported a 102% increase in revenue in the second quarter (108% currency-adjusted), driven by strong US growth and a doubling of patch sales in the US. System deliveries rose 53% to 29 units, operating expenses fell 19% quarter-on-quarter, and liquid funds were around 29 million SEK. Despite the progress, the company remained unprofitable with a net loss of 9.4 million SEK, and the stock fell 3.29% pre-market. Management highlights additional growth drivers such as CPT-1 reimbursement in the US, international approvals and ongoing investments in commercialization. » Altro su de.investing.com

Acarix reported Q2 2026 revenue of about SEK 2.3m, up 102% (currency-adjusted 108%), with US sales growing 212–223%. System deliveries rose 53% in the quarter to 29 units and US sales of patches doubled to 140 packs. Operating expenses fell 19% versus the prior quarter, net loss was SEK 9.4m, cash was around SEK 29m and monthly cash burn about SEK 3m. Management sees drivers in US reimbursement (target: CPT-1 in H1 2027), an ongoing US performance study with publication expected before end-2026, and international expansion, but warns of continued uneven growth and reimbursement risks. » Altro su de.investing.com

Acarix reports Q4 2025 revenue of SEK 2,141k, up 26% year‑on‑year, driven by an 87% revenue jump in the US. CADScor system shipments rose 64% to 23 units and consumables sales increased 73%, indicating higher system utilization. Operating costs fell 23% and the net loss improved by 27%, while the monthly burn rate declined by 37%. Growing reimbursement in the US, EU‑MDR certification and a sales agreement in Saudi Arabia underpin the expansion strategy. » Altro su de.investing.com